-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
December 19, 2021/MedClub News/--Inceptor Bio, the next-generation cell therapy and gene therapy biotechnology company M) The platform officially signed a license agreement to accelerate the company's research on refractory cancers
.
This technique was discovered by Dr.
Denise Montell's UCSB research laboratory
.
Dr.
Denise Montell has in-depth research on macrophages, and this collaboration will help transform decades of basic scientific research into cancer immunotherapy
.
Macrophages naturally engulf viruses and bacteria through phagocytosis.
When macrophages combine with CAR to form CAR-M, they endow the macrophages with selectivity, allowing them to accurately target and engulf cancer cells, and regulate tumors.
The microenvironment produces an immune response
.
Inceptor's CAR-M technology builds on this foundation and plans to optimize the effectiveness of this treatment
.
Founded in 2020, the biotechnology company Inceptor Bio is committed to the development of diverse next-generation cell and gene therapy platforms, including CAR-T, CAR-M, and CAR-NK/NKT, to provide treatments for unmet needs and refractory cancers Method
.
By collaborating with universities, medical centers, and industry leaders, Inceptor Bio plans to advance the discovery stage technology to the clinical stage
.
Inceptor Bio is also investing in its advanced manufacturing platform, AMP+, as a shared infrastructure with suitable use, high capital efficiency, and scalability to support the development of diversified cell and gene therapy platforms across cell types
.
▲ Inceptor Bio's technology platform (picture source: the company's official website) In June this year, Inceptor Bio has raised $26 million in seed round financing to create a series of next-generation cell and gene therapy subsidiaries based on its advanced manufacturing platform (AMP+) Develop diversified therapies
.
Recommended reading: Drug financingInceptor Bio announced the completion of a seed round of $26 million to develop next-generation cell and gene therapies for cancer.
In July of this year, Inceptor Bio announced the launch of FastBack Bio, a subsidiary with a new CAR-T platform
.
The core technology of FastBack Bio is the costimulation domain platform M-STIM, licensed from the University of North Carolina at Chapel Hill
.
The M-STIM costimulatory domain can help T cells activate, continue to exert anti-tumor effects, and endow CAR-T cells with many beneficial properties
.
The in vitro data of the first costimulatory domain M83 in the M-STIM platform shows that the costimulatory domain M83 can provide CAR-T cells with stronger expansion capabilities and can improve the tumor microenvironment
.
Recommended reading: The new company brings a better CAR structure, and the new strategic layout of a diversified cell therapy platformYimai Meng broke the news about CAR therapy that is full of flowers.
Today, CAR-T has entered the commercialization stage at home and abroad, and there are many more CAR technology study on other cells, derived therefrom, a series of CAR-NK, CAR-NKT, CAR-M, CAR-Treg, CAR γδ-T, CAR-CIK cells such as through the following treatment
.
Recently, CAR therapy has also ushered in many results
.
➤ The pioneer of CAR-MCAR-M and the lead drug of Carisma Therapeutics founded by Penn scientists, targeting HER2 CT-0508, was approved by the FDA to enter clinical research last year, becoming the first CAR-M therapy to enter the clinic for treatment HER2-positive solid tumors
.
In March of this year, CT-0508 completed the first subject administration, marking a new era in the treatment of solid tumors by macrophages
.
Earlier this month, Carisma announced a collaboration with Merck to evaluate the combination of CAR-M and KEYTRUDA in a variety of HER2 overexpressing solid tumors
.
Recommended reading: Combination of CAR-M and anti-PD-1 therapy to target solid tumorsYi Meng broke the news ➤ CAR-CIK has certain limitations (including toxicity, tumor microenvironment limitations, etc.
) in the treatment of solid tumors with CAR-T cells
.
CoImmune's allogeneic CAR-CIK (cytokine-induced killer cell) technology has the potential to greatly reduce toxicity and improve the efficacy and durability of CAR-CIK in the tumor microenvironment
.
CIK cells refer to a group of heterogeneous cells obtained from mononuclear cells derived from peripheral blood/bone marrow/umbilical blood after being stimulated and cultured by various cytokines (such as anti-CD3 monoclonal antibodies, IL-2 and IFN-γ, etc.
)
.
CIK cells have the killing mechanism of T cells and NK cells, and at the same time can resist the induction of GVHD
.
Not long ago, the clinical-stage immuno-oncology company CoImmune announced the results of a phase 1/2 clinical trial of allogeneic CAR-CIK (cytokine-induced killer cell) targeting CD19.
The results showed that the drug can be used in allogeneic hematopoiesis.
After stem cell transplantation (HSCT), children and adults with acute lymphoblastic leukemia (ALL) showed a high degree of safety, and 61.
9% of patients achieved complete remission
.
▲ Advantages of CIK cells (picture source: CoImmune official website) ➤ CAR γδ-Tγδ T cells are known as a natural killer, also known as "a great candidate for CAR-T cells
.
"
γδ T cells refer to T cells with γδ-type receptors with γ chain and δ chain.
Different from αβ T cells that are usually used to prepare CAR-T therapy, γδ T cells are part of the innate immune system and only occupy all of the human body.
About 5% of the number of T cells
.
This month, Adicet Bio announced that a dose-escalation phase 1 clinical trial of the allogeneic, "ready-to-use" CD20 targeting CAR γδ-T cell therapy ADI-001 has obtained positive interim data
.
The phase I clinical trial of ADI-001 mainly verified its safety and tolerability.
The results of the interim trial showed that 3 out of 4 evaluable patients achieved remission, including 2 complete remissions (CR) and 1 partial remission ( PR), dose-limiting toxicity, graft-versus-host disease, immune effector cell-related neurotoxicity syndrome, or grade 3 or higher cytokine release syndrome has not been found
.
Recommended reading: "Spot" CAR-γδ T therapy announced the latest clinical data: up to 75% remission rate! Yimai Meng broke the news ➤ CAR-NK cell therapy NK cells are the immune system’s first line of defense against diseases and pathogens, and an important part of the innate immune system.
It plays a role with cytotoxic T cells in the acquired immune system.
The role of tumor killer
.
On November 11 this year, the Drug Evaluation Center of the China National Medical Products Administration approved the targeted mesothelin (MSLN) developed by Guojian Chengnuo Biotechnology (Beijing) Co.
, Ltd.
for the treatment of advanced epithelial ovarian cancer.
) Application for clinical trial of chimeric antigen receptor NK cell (CAR-NK) injection" (abbreviation: CAR-NK injection)
.
This product is the first domestic CAR-NK product of "spot type" allogeneic origin officially approved by the National Center for Drug Evaluation, marking a new milestone in the research of immune cell drug treatment of solid tumors.
.
Recommended reading: Guojian Chengnuo obtained the first domestic "spot type" CAR-NK cell drug IND approval ➤ CAR-iNKT cell therapy Natural killer T cells (NKT) are a unique subgroup of T lymphocytes and are considered to be the fourth Lymphocyte-like
.
According to the type of TCR it expresses and whether antigen recognition depends on CD1d molecules, NKT cells can be divided into type I, type II and type III
.
Among them, type I NKT cells are constant natural killer T cells (iNKT), which bridge innate immunity and acquired immunity, and mainly exist in tissues such as liver and bone marrow
.
Although the number is rare, it plays an important role in the occurrence and development of a variety of diseases, including autoimmune diseases, infections and malignant tumors
.
iNKT cells have the characteristics of both NK cells and T cells, and express invariable T cell receptor (TCR) and NK cell surface markers (CD161 in humans), and can recognize non-polymorphic MHC class 1 molecules CD1d The presented glycolipid antigens are activated by the interaction of NKG2D-NKG2D ligands and cytokines
.
In August of this year, Kite Pharma, a subsidiary of Gilead, announced that it has reached a cooperation and licensing agreement with Appia Bio, a biotechnology start-up company.
The two companies will develop CAR-iNKT derived from hematopoietic stem cells based on Appia Bio’s allogeneic cell therapy technology platform.
Cell therapy is used for cancer treatment
.
Recommended reading: Gilead/Kite invested 875 million US dollars to jointly develop allogeneic CAR-iNKT cell therapyYi Mai Meng broke the news.
Reference materials: 1.
https:// bio-enters-into-in-licensing-agreement-with-university-of-california-santa-barbara-for-car-m-platform-301445941.
htmlRecommended articles
.
This technique was discovered by Dr.
Denise Montell's UCSB research laboratory
.
Dr.
Denise Montell has in-depth research on macrophages, and this collaboration will help transform decades of basic scientific research into cancer immunotherapy
.
Macrophages naturally engulf viruses and bacteria through phagocytosis.
When macrophages combine with CAR to form CAR-M, they endow the macrophages with selectivity, allowing them to accurately target and engulf cancer cells, and regulate tumors.
The microenvironment produces an immune response
.
Inceptor's CAR-M technology builds on this foundation and plans to optimize the effectiveness of this treatment
.
Founded in 2020, the biotechnology company Inceptor Bio is committed to the development of diverse next-generation cell and gene therapy platforms, including CAR-T, CAR-M, and CAR-NK/NKT, to provide treatments for unmet needs and refractory cancers Method
.
By collaborating with universities, medical centers, and industry leaders, Inceptor Bio plans to advance the discovery stage technology to the clinical stage
.
Inceptor Bio is also investing in its advanced manufacturing platform, AMP+, as a shared infrastructure with suitable use, high capital efficiency, and scalability to support the development of diversified cell and gene therapy platforms across cell types
.
▲ Inceptor Bio's technology platform (picture source: the company's official website) In June this year, Inceptor Bio has raised $26 million in seed round financing to create a series of next-generation cell and gene therapy subsidiaries based on its advanced manufacturing platform (AMP+) Develop diversified therapies
.
Recommended reading: Drug financingInceptor Bio announced the completion of a seed round of $26 million to develop next-generation cell and gene therapies for cancer.
In July of this year, Inceptor Bio announced the launch of FastBack Bio, a subsidiary with a new CAR-T platform
.
The core technology of FastBack Bio is the costimulation domain platform M-STIM, licensed from the University of North Carolina at Chapel Hill
.
The M-STIM costimulatory domain can help T cells activate, continue to exert anti-tumor effects, and endow CAR-T cells with many beneficial properties
.
The in vitro data of the first costimulatory domain M83 in the M-STIM platform shows that the costimulatory domain M83 can provide CAR-T cells with stronger expansion capabilities and can improve the tumor microenvironment
.
Recommended reading: The new company brings a better CAR structure, and the new strategic layout of a diversified cell therapy platformYimai Meng broke the news about CAR therapy that is full of flowers.
Today, CAR-T has entered the commercialization stage at home and abroad, and there are many more CAR technology study on other cells, derived therefrom, a series of CAR-NK, CAR-NKT, CAR-M, CAR-Treg, CAR γδ-T, CAR-CIK cells such as through the following treatment
.
Recently, CAR therapy has also ushered in many results
.
➤ The pioneer of CAR-MCAR-M and the lead drug of Carisma Therapeutics founded by Penn scientists, targeting HER2 CT-0508, was approved by the FDA to enter clinical research last year, becoming the first CAR-M therapy to enter the clinic for treatment HER2-positive solid tumors
.
In March of this year, CT-0508 completed the first subject administration, marking a new era in the treatment of solid tumors by macrophages
.
Earlier this month, Carisma announced a collaboration with Merck to evaluate the combination of CAR-M and KEYTRUDA in a variety of HER2 overexpressing solid tumors
.
Recommended reading: Combination of CAR-M and anti-PD-1 therapy to target solid tumorsYi Meng broke the news ➤ CAR-CIK has certain limitations (including toxicity, tumor microenvironment limitations, etc.
) in the treatment of solid tumors with CAR-T cells
.
CoImmune's allogeneic CAR-CIK (cytokine-induced killer cell) technology has the potential to greatly reduce toxicity and improve the efficacy and durability of CAR-CIK in the tumor microenvironment
.
CIK cells refer to a group of heterogeneous cells obtained from mononuclear cells derived from peripheral blood/bone marrow/umbilical blood after being stimulated and cultured by various cytokines (such as anti-CD3 monoclonal antibodies, IL-2 and IFN-γ, etc.
)
.
CIK cells have the killing mechanism of T cells and NK cells, and at the same time can resist the induction of GVHD
.
Not long ago, the clinical-stage immuno-oncology company CoImmune announced the results of a phase 1/2 clinical trial of allogeneic CAR-CIK (cytokine-induced killer cell) targeting CD19.
The results showed that the drug can be used in allogeneic hematopoiesis.
After stem cell transplantation (HSCT), children and adults with acute lymphoblastic leukemia (ALL) showed a high degree of safety, and 61.
9% of patients achieved complete remission
.
▲ Advantages of CIK cells (picture source: CoImmune official website) ➤ CAR γδ-Tγδ T cells are known as a natural killer, also known as "a great candidate for CAR-T cells
.
"
γδ T cells refer to T cells with γδ-type receptors with γ chain and δ chain.
Different from αβ T cells that are usually used to prepare CAR-T therapy, γδ T cells are part of the innate immune system and only occupy all of the human body.
About 5% of the number of T cells
.
This month, Adicet Bio announced that a dose-escalation phase 1 clinical trial of the allogeneic, "ready-to-use" CD20 targeting CAR γδ-T cell therapy ADI-001 has obtained positive interim data
.
The phase I clinical trial of ADI-001 mainly verified its safety and tolerability.
The results of the interim trial showed that 3 out of 4 evaluable patients achieved remission, including 2 complete remissions (CR) and 1 partial remission ( PR), dose-limiting toxicity, graft-versus-host disease, immune effector cell-related neurotoxicity syndrome, or grade 3 or higher cytokine release syndrome has not been found
.
Recommended reading: "Spot" CAR-γδ T therapy announced the latest clinical data: up to 75% remission rate! Yimai Meng broke the news ➤ CAR-NK cell therapy NK cells are the immune system’s first line of defense against diseases and pathogens, and an important part of the innate immune system.
It plays a role with cytotoxic T cells in the acquired immune system.
The role of tumor killer
.
On November 11 this year, the Drug Evaluation Center of the China National Medical Products Administration approved the targeted mesothelin (MSLN) developed by Guojian Chengnuo Biotechnology (Beijing) Co.
, Ltd.
for the treatment of advanced epithelial ovarian cancer.
) Application for clinical trial of chimeric antigen receptor NK cell (CAR-NK) injection" (abbreviation: CAR-NK injection)
.
This product is the first domestic CAR-NK product of "spot type" allogeneic origin officially approved by the National Center for Drug Evaluation, marking a new milestone in the research of immune cell drug treatment of solid tumors.
.
Recommended reading: Guojian Chengnuo obtained the first domestic "spot type" CAR-NK cell drug IND approval ➤ CAR-iNKT cell therapy Natural killer T cells (NKT) are a unique subgroup of T lymphocytes and are considered to be the fourth Lymphocyte-like
.
According to the type of TCR it expresses and whether antigen recognition depends on CD1d molecules, NKT cells can be divided into type I, type II and type III
.
Among them, type I NKT cells are constant natural killer T cells (iNKT), which bridge innate immunity and acquired immunity, and mainly exist in tissues such as liver and bone marrow
.
Although the number is rare, it plays an important role in the occurrence and development of a variety of diseases, including autoimmune diseases, infections and malignant tumors
.
iNKT cells have the characteristics of both NK cells and T cells, and express invariable T cell receptor (TCR) and NK cell surface markers (CD161 in humans), and can recognize non-polymorphic MHC class 1 molecules CD1d The presented glycolipid antigens are activated by the interaction of NKG2D-NKG2D ligands and cytokines
.
In August of this year, Kite Pharma, a subsidiary of Gilead, announced that it has reached a cooperation and licensing agreement with Appia Bio, a biotechnology start-up company.
The two companies will develop CAR-iNKT derived from hematopoietic stem cells based on Appia Bio’s allogeneic cell therapy technology platform.
Cell therapy is used for cancer treatment
.
Recommended reading: Gilead/Kite invested 875 million US dollars to jointly develop allogeneic CAR-iNKT cell therapyYi Mai Meng broke the news.
Reference materials: 1.
https:// bio-enters-into-in-licensing-agreement-with-university-of-california-santa-barbara-for-car-m-platform-301445941.
htmlRecommended articles
